<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-28-01-2026-shutterstock_2306050281-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-28-01-2026-shutterstock_2306050281-430x241.jpg"/></p>
<p>英矽智能的商業模式包括與 13 家跨國製藥公司進行軟件解決方案授權。圖片來源：metamorworks / Shutterstock.com。</p>
<p>英矽智能與齊魯製藥及其子公司上海齊魯製藥研究中心在心臟代謝疾病的藥物開發方面達成戰略合作。</p>
<p>該合作將利用英矽智能的 Pharma.AI 平台開發小分子抑制劑，協議價值近 1.2 億美元。</p>
<p>該協議包括開發和商業里程碑付款，以及基於淨銷售額的單數字版税。</p>
<p>根據協議，英矽智能將設計和優化用於治療代謝疾病的小分子。</p>
<p>齊魯製藥將負責後續的開發和商業化活動。</p>
<p>英矽智能的商業模式包括與 13 家跨國製藥公司進行軟件解決方案授權，以及與賽諾菲和復星醫藥的研究合作，涉及預付款項。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>由 GlobalData 提供</p>
<p>該公司還將與 Menarini 集團和 Exelixis 簽署總額超過 20 億美元的管線外授權協議。</p>
<p>齊魯製藥於 2021 年首次採用 PandaOmics，這促成了此次新的 1.2 億美元合作。</p>
<p>英矽智能創始人、首席執行官兼首席商務官亞歷克斯·扎沃倫科表示：“我們很高興看到英矽智能與齊魯製藥進一步深化由生成性人工智能驅動的戰略合作。</p>
<p>“我相信，針對心臟代謝疾病的策略有潛力產生首批實現大規模健康壽命延長的藥物，我期待人工智能技術加速該領域的創新並最大化潛力。”</p>
<p>在 2025 年 3 月，英矽智能完成了一輪 E 輪融資，籌集了 1.1 億美元，以推進其藥物管線和人工智能平台的發展。</p>

英矽智能

<p>英矽智能與齊魯製藥簽署了一項價值 1.2 億美元的協議，旨在利用英矽智能的 Pharma.AI 平台開發心臟代謝療法。該協議包括里程碑付款和基於淨銷售的特許權使用費。英矽智能將設計用於代謝疾病的小分子，而齊魯製藥將負責開發和商業化。這一合作建立在齊魯製藥 2021 年採用英矽智能的 PandaOmics 基礎之上。英矽智能的首席執行官對人工智能在加速心臟代謝疾病藥物創新方面的潛力表示樂觀</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-28-01-2026-shutterstock_2306050281-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-28-01-2026-shutterstock_2306050281-430x241.jpg"/></p>
<p>Insilico’s business model includes software solution licensing with 13 multinational pharma companies. Credit: metamorworks / Shutterstock.com.</p>
<div class="lb-trans"><p>英矽智能的商業模式包括與 13 家跨國製藥公司進行軟件解決方案授權。圖片來源：metamorworks / Shutterstock.com。</p>
</div><p>Insilico Medicine has entered a strategic partnership with Qilu Pharmaceutical and its subsidiary Shanghai Qilu Pharmaceutical Research Center on drug development for cardiometabolic diseases.</p>
<div class="lb-trans"><p>英矽智能與齊魯製藥及其子公司上海齊魯製藥研究中心在心臟代謝疾病的藥物開發方面達成戰略合作。</p>
</div><p>The partnership will leverage Insilico’s Pharma.AI platform for the development of small molecule inhibitors, with the agreement valued at nearly $120m.</p>
<div class="lb-trans"><p>該合作將利用英矽智能的 Pharma.AI 平台開發小分子抑制劑，協議價值近 1.2 億美元。</p>
</div><p>This agreement includes development and commercial milestone payments plus single-digit royalties based on net sales.</p>
<div class="lb-trans"><p>該協議包括開發和商業里程碑付款，以及基於淨銷售額的單數字版税。</p>
</div><p>Under the agreement, Insilico will design and optimise small molecules for treating metabolic disorders.</p>
<div class="lb-trans"><p>根據協議，英矽智能將設計和優化用於治療代謝疾病的小分子。</p>
</div><p>Qilu Pharmaceutical will oversee subsequent development and commercialisation activities.</p>
<div class="lb-trans"><p>齊魯製藥將負責後續的開發和商業化活動。</p>
</div><p>Insilico’s business model includes software solution licensing with 13 multinational pharma companies, research collaborations involving upfront payments with Sanofi and Fosun Pharma.</p>
<div class="lb-trans"><p>英矽智能的商業模式包括與 13 家跨國製藥公司進行軟件解決方案授權，以及與賽諾菲和復星醫藥的研究合作，涉及預付款項。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>The company will also sign pipeline out-licensing deals with Menarini Group and Exelixis totalling more than $2bn.</p>
<div class="lb-trans"><p>該公司還將與 Menarini 集團和 Exelixis 簽署總額超過 20 億美元的管線外授權協議。</p>
</div><p>Qilu Pharmaceutical initially adopted PandaOmics in 2021, which led to this new $120m collaboration.</p>
<div class="lb-trans"><p>齊魯製藥於 2021 年首次採用 PandaOmics，這促成了此次新的 1.2 億美元合作。</p>
</div><p>Insilico founder, CEO and chief business officer Alex Zhavoronkov said: “We are pleased to see Insilico Medicine and Qilu Pharmaceutical further deepen their strategic collaboration driven by generative AI.</p>
<div class="lb-trans"><p>英矽智能創始人、首席執行官兼首席商務官亞歷克斯·扎沃倫科表示：“我們很高興看到英矽智能與齊魯製藥進一步深化由生成性人工智能驅動的戰略合作。</p>
</div><p>“I believe that strategies targeting cardiometabolic diseases have the potential to generate the first drugs to achieve large-scale healthspan extension, and I look forward to AI technology accelerating innovation in the field and maximising potential.”</p>
<div class="lb-trans"><p>“我相信，針對心臟代謝疾病的策略有潛力產生首批實現大規模健康壽命延長的藥物，我期待人工智能技術加速該領域的創新並最大化潛力。”</p>
</div><p>In March 2025, Insilico Medicine completed a Series E financing round, raising $110m to progress the development of its pipeline of drugs and AI platform.</p>
<div class="lb-trans"><p>在 2025 年 3 月，英矽智能完成了一輪 E 輪融資，籌集了 1.1 億美元，以推進其藥物管線和人工智能平台的發展。</p>
</div>

英矽智能與齊魯製藥簽署心臟代謝治療協議